The Supreme Court appears likely to reject a challenge to the abortion pill mifepristone, focusing on legal standing rather than the FDA's decisions. The case is a major test for the conservative-majority court after overturning Roe v. Wade.
Key Points
Focus on legal standing rather than FDA's decisions
Conservative-majority court's test post overturning Roe v. Wade
Potential nationwide impact on abortion access
Pros
Focus on legal standing may limit the scope of the case
FDA's decisions on the abortion pill's availability may not be questioned
Cons
Restrictions on access to the abortion pill could be upheld
Potential impact on abortion rights and access if the challenge is successful